Deal Watch: Sanofi To Tap Owkin’s AI, Machine Learning In Oncology
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
You may also be interested in...
Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.
Roche has bowed out of the race to develop an oral COVID-19 therapy, leaving a lucrative but likely short-lived market for its rivals.